Guardian Pharmacy Services (NYSE:GRDN) Price Target Raised to $24.00

Guardian Pharmacy Services (NYSE:GRDN) had its price target hoisted by equities research analysts at Truist Financial from $22.00 to $24.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 14.67% from the stock’s previous close.

A number of other brokerages have also commented on GRDN. Raymond James initiated coverage on Guardian Pharmacy Services in a research report on Monday, October 21st. They issued an “outperform” rating and a $21.00 target price on the stock. Stephens initiated coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an “overweight” rating and a $21.00 price objective on the stock.

Guardian Pharmacy Services Stock Performance

NYSE:GRDN opened at $20.93 on Friday. Guardian Pharmacy Services has a twelve month low of $14.16 and a twelve month high of $23.05.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($2.00) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($2.19). The firm had revenue of $314.39 million for the quarter, compared to analysts’ expectations of $303.21 million. Sell-side analysts forecast that Guardian Pharmacy Services will post 0.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardian Pharmacy Services

In other news, Director Thomas J. Salentine, Jr. acquired 35,714 shares of the business’s stock in a transaction on Friday, September 27th. The stock was bought at an average price of $14.00 per share, with a total value of $499,996.00. Following the completion of the acquisition, the director now owns 35,714 shares of the company’s stock, valued at approximately $499,996. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Hedge Funds Weigh In On Guardian Pharmacy Services

Several institutional investors and hedge funds have recently modified their holdings of GRDN. Stephens Inc. AR acquired a new stake in Guardian Pharmacy Services in the third quarter valued at approximately $189,000. Barclays PLC purchased a new position in shares of Guardian Pharmacy Services during the 3rd quarter valued at approximately $311,000. Point72 DIFC Ltd acquired a new stake in Guardian Pharmacy Services in the 3rd quarter valued at $573,000. Royce & Associates LP purchased a new stake in Guardian Pharmacy Services in the 3rd quarter worth $1,260,000. Finally, Foundry Partners LLC acquired a new position in Guardian Pharmacy Services during the third quarter worth $1,680,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.